The group's principal activity is to license, develop and commercialize both therapeutic and molecular imaging/diagnostic products. The group develops and improves diagnosis and treatment of prostate cancer and other areas of oncology. The group also conducts research in cell signaling through its subsidiary, axcell biosciences. The products include quadramet, prostascint, and nmp22 bladderchek. The group operates in United States.
